Holen Sie sich die Stockscreener-App
2.02
1.94%
-0.04
Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships - Macau Business
Jyong Biotech Ltd (MENS) Institutional Confidence - TradingKey
Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jyong Biotech Ltd (MENS) Income Statement - TradingKey
Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MENS|Jyong Biotech Ltd|Price:2.360|Chg%:-0.350 - TradingKey
Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jyong Biotech Ltd (MENS) Balance Sheet - TradingKey
Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jyong Biotech pursues global licensing partnerships for BPH drug By Investing.com - Investing.com Nigeria
Jyong Biotech targets $22B global BPH market wi... - Pluang
Jyong Biotech pursues global licensing partnerships for BPH drug - Investing.com
Jyong Biotech Ltd. Reaffirms Global Licensing Strategy for Botanical BPH Drug Candidate Botreso - Quiver Quantitative
Benign prostatic hyperplasia patients projected to reach 150M-156M by 2035 - Stock Titan
Jyong Biotech (MENS) Gains 3.88% as Positive Momentum Targets Key ResistanceHead and Shoulders - dars.gov.et
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 36.2% in June - MarketBeat
Jyong Biotech (MENS) Dips 1.3% as Stock Approaches Key Support at $2.16Bollinger Squeeze - dars.gov.et
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - Macau Business
Jyong Biotech presents drug candidate at BIO 2026 convention By Investing.com - Investing.com Nigeria
Jyong Biotech presents drug candidate at BIO 2026 convention - Investing.com
Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment. - Pluang
Jyong Biotech (MENS) Retreats Over 5% as Key Support Test LoomsForce Index - dars.gov.et
Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBITDA forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd. (MENS) Modest Gain Amidst Tight Trading RangeDefined Outcome ETF - DonanımHaber
Jyong Biotech Ltd (MENS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Number of shareholders of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd (MENS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate
MENSJyong Biotech Ltd Stock Price and Quote - Finviz
Jyong Biotech Ltd. (MENS) Rises 2.36% as Stock Approaches Key ResistanceEarnings Quality Factor - dars.gov.et
Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - marketscreener.com
Jyong Biotech (NASDAQ: MENS) flags Botreso FDA hurdles and $19.4M judgment - Stock Titan
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025 - Quiver Quantitative
DXS INTERNATIONAL PLC (AQSE: DXSP): Issue of New Shares and Notification of Director / PDMR Dealings - Weekly Voice
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):